About Otimoinvest

What we do

Otimoinvest tracks clinical-stage biotech companies, aggregating pipeline data, FDA milestones and upcoming trial readouts into a structured, continuously updated resource. Our data is drawn from public sources including the FDA and ClinicalTrials.gov.

Editorial approach

We publish educational analysis, not investment recommendations. Every page is built to help readers understand catalysts and clinical progress — the reasoning, not the verdict.

Contact

For corrections, data questions or editorial enquiries: editor@otimoinvest.com